JP6112316B2 - テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用 - Google Patents

テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用 Download PDF

Info

Publication number
JP6112316B2
JP6112316B2 JP2014547736A JP2014547736A JP6112316B2 JP 6112316 B2 JP6112316 B2 JP 6112316B2 JP 2014547736 A JP2014547736 A JP 2014547736A JP 2014547736 A JP2014547736 A JP 2014547736A JP 6112316 B2 JP6112316 B2 JP 6112316B2
Authority
JP
Japan
Prior art keywords
mmol
title compound
tetraaza
cyclopenta
hplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014547736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502371A5 (https=
JP2015502371A (ja
Inventor
ドミニク スウィンネン
ドミニク スウィンネン
シリル モンターニュ
シリル モンターニュ
ヴァンサン ポメル
ヴァンサン ポメル
アンナ クアトロパーニ
アンナ クアトロパーニ
ジェローム モレット
ジェローム モレット
パトリック ゲルバー
パトリック ゲルバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11195214.9A external-priority patent/EP2607364A1/en
Priority claimed from EP12171415.8A external-priority patent/EP2674434A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2015502371A publication Critical patent/JP2015502371A/ja
Publication of JP2015502371A5 publication Critical patent/JP2015502371A5/ja
Application granted granted Critical
Publication of JP6112316B2 publication Critical patent/JP6112316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2014547736A 2011-12-22 2012-11-30 テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用 Active JP6112316B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161578931P 2011-12-22 2011-12-22
US61/578,931 2011-12-22
EP11195214.9 2011-12-22
EP11195214.9A EP2607364A1 (en) 2011-12-22 2011-12-22 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US201261657978P 2012-06-11 2012-06-11
EP12171415.8A EP2674434A1 (en) 2012-06-11 2012-06-11 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
EP12171415.8 2012-06-11
US61/657,978 2012-06-11
PCT/EP2012/004968 WO2013091773A1 (en) 2011-12-22 2012-11-30 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators

Publications (3)

Publication Number Publication Date
JP2015502371A JP2015502371A (ja) 2015-01-22
JP2015502371A5 JP2015502371A5 (https=) 2016-08-04
JP6112316B2 true JP6112316B2 (ja) 2017-04-12

Family

ID=48667735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014547736A Active JP6112316B2 (ja) 2011-12-22 2012-11-30 テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用

Country Status (8)

Country Link
US (1) US9403835B2 (https=)
EP (1) EP2794608B1 (https=)
JP (1) JP6112316B2 (https=)
CN (1) CN104039789B (https=)
AU (1) AU2012357169B2 (https=)
CA (1) CA2860008C (https=)
ES (1) ES2606839T3 (https=)
WO (1) WO2013091773A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813505A1 (en) * 2013-06-14 2014-12-17 Asceneuron SA Tetraaza-cyclopenta[a]indenyl derivatives
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CN106573928B (zh) * 2014-08-26 2020-04-14 安斯泰来制药株式会社 2-氨基噻唑衍生物或其盐
KR102623321B1 (ko) * 2015-02-11 2024-01-09 선오비온 파마슈티컬스 인코포레이티드 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체
EP3342777B1 (en) * 2015-08-28 2023-01-11 Sekisui Medical Co., Ltd. Benzyl compound
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392692B1 (en) 2001-03-27 2006-11-15 Neurogen Corporation (oxo-pyrazolo¬1,5a|pyrimidin-2-yl)alkyl-carboxamides
ATE457989T1 (de) * 2004-12-15 2010-03-15 Hoffmann La Roche Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
US7855206B2 (en) * 2006-11-14 2010-12-21 Merck Sharp & Dohme Corp. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2011137049A1 (en) * 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived m1 receptor positive allosteric modulators
EP2813505A1 (en) * 2013-06-14 2014-12-17 Asceneuron SA Tetraaza-cyclopenta[a]indenyl derivatives

Also Published As

Publication number Publication date
CN104039789A (zh) 2014-09-10
AU2012357169A1 (en) 2014-08-07
AU2012357169B2 (en) 2017-03-30
EP2794608A1 (en) 2014-10-29
CA2860008A1 (en) 2013-06-27
US20150018343A1 (en) 2015-01-15
EP2794608B1 (en) 2016-09-14
CN104039789B (zh) 2016-09-07
CA2860008C (en) 2020-11-10
ES2606839T3 (es) 2017-03-28
JP2015502371A (ja) 2015-01-22
WO2013091773A1 (en) 2013-06-27
US9403835B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
JP6112316B2 (ja) テトラアザ−シクロペンタ［ａ］インデニル及びポジティブアロステリックモジュレーターとしてのそれらの使用
EP0239309B1 (en) Oxadiazoles useful in the treatment of senile dementia
TWI468402B (zh) 降低β－類澱粉生成之化合物
RU2448105C2 (ru) 2-аминобензоксазолкарбоксамиды в качестве модуляторов 5-нт3
KR20200100709A (ko) 4-아자인돌 화합물
JP2025186255A (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物
KR20190076032A (ko) 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물
CN102056933B (zh) 作为白三烯a4水解酶调节剂的噻唑并吡啶-2-基氧基-苯基和噻唑并吡嗪-2-基氧基-苯基胺类
CN121773115A (zh) 作为CDKs抑制剂的新型并杂环类新化合物及其应用
EP3844159B1 (en) Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease
CA2745721C (en) Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
WO2020048605A1 (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease
AU2006236625A1 (en) N-alkyl-azacycloalkyl NMDA/NR2B antagonists
EP2989104B1 (en) Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments
JP2024536237A (ja) Ｔｒｐｍｌの調整剤、その組成物及び使用方法
EP3008068B1 (en) Tetraaza-cyclopenta[a]indenyl derivatives
EP2674434A1 (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
WO2026024861A1 (en) Compounds targeting mutations in p53 and uses thereof
EP2607364A1 (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
WO2026024896A1 (en) Compounds targeting mutations in p53 and uses thereof
TW202508565A (zh) Kv1.3鉀通道拮抗劑
KR20260057425A (ko) 화합물, 조성물, 및 방법

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170228

R150 Certificate of patent or registration of utility model

Ref document number: 6112316

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250